Hospitalization due to whooping cough in Spain (1997-2011);Hospitalización portos ferina en España (1997-2011)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 32, Issue 10, 2014, Pages 638-642

  Fernández Cano, María Isabel ^a   Armadans Gil, Lluís ^b   Álvarez Bartolomé, Mercedes ^c   Rodrigo Pendás, José Ángel ^b   Campins Martí, Magda ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Instituto de Informacion Sanitaria   (Spain)

Author keywords

Epidemiology; Health care surveys; Hospitalization; National hospital discharge survey; Whooping cough

Indexed keywords

AGED; ARTICLE; CHILD; CHILD HOSPITALIZATION; DEATH; HOSPITAL DISCHARGE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INCIDENCE; LETHALITY; MAJOR CLINICAL STUDY; MORTALITY; PERTUSSIS; RETROSPECTIVE STUDY; SAMPLE SIZE; SPAIN; ADOLESCENT; ADULT; COST; ECONOMICS; FEMALE; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TIME FACTOR; WHOOPING COUGH; YOUNG ADULT; AGE DISTRIBUTION; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; REVIEW; TREND STUDY; VULNERABLE POPULATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; WHOOPING COUGH; YOUNG ADULT;

EID: 84927696978     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2013.11.006     Document Type: Article

References (33)

1. Cherry JD Epidemic pertussis in 2012 -the resurgence of a vaccine-preventable disease. N EnglJ Med. 2012; 367: 785-7.
2. Moraga-Llop FA, Campins-Martí M. New perspectives on whooping cough in the 21st century. Are we failing to control it? Enferm Infecc Microbiol Clin. 2011; 29: 561-3.
3. Ministerio de Sanidad, Servicios Sociales e Igualdad. Coberturas de Vacunación [consultado 16 Jul 2013]. Disponible en: http://www.msps.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm
4. Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005; 24:S58-61.
5. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012; 54: 1730-5.
6. Zhang L, Prietsch SOM, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane database Syst Rev. 2012; 3:CD001478.
7. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 - conclusions and recommendations. Wkly Epidemiol Rec. 2009; 84: 517-32.
8. Liu BC, McIntyre P, Kaldor JM, Quinn HE, Ridda I, Banks E. Pertussis in older adults: Prospective study of risk factors and morbidity. Clin Infect Dis. 2012; 55: 1450-6.
9. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis epidemic, 2010. J Pediatr. 2012; 161: 1091-6.
10. Centers for Disease Control and Prevention. Pertussis-United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002; 51: 73-6.
11. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2012; 61: 468-70.
12. Moraga F, Roca J, Méndez C, Rodrigo C, Pineda V, Martinez A, et al. Epidemiology and surveillance of pertussis among infants in Catalonia, Spain, during 1997-2001. Pediatr Infect Dis J. 2005; 24: 510-3.
13. Torvaldsen S, McIntyre P. Do variations in pertussis notifications reflect incidence or surveillance practices? A comparison of infant notification rates and hospitalisation data in NSW. NSW Public Health Bull. 2003; 14: 81-4.
14. Guiso N, Wirsing von König CH, Forsyth K, Tan T, Plotkin SA. The Global Pertussis Initiative: Report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine. 2011; 29: 1115-21.
15. Instituto Nacional de Estadística. INEbase [consultado 16 Jul 2013]. Disponible en: http://www.ine.es/inebmenu/mnu-cifraspob.htm
16. Ministerio Sanidad, Servicios Sociales e Igualdad. Instituto de Información Sanitaria. Análisis y desarrollo de los GDR en el Sistema Nacional de Salud [consultado 16 Jul 2013]. Disponible en: http://www.msssi.gob.es/estadEstudios/estadisticas/docs/analisis.pdf
17. Santos JM, Gil R, Álvaro A, Gil A. Epidemiología de las hospitalizaciones atribuibles a infección por Bordetella pertussis en población general en España (1999-2005). Vacunas. 2008; 9: 50-6.
18. Spokes PJ, Gilmour RE. NSW annual vaccine-preventable disease report, 2010. NSW Public Health Bull. 2011; 22: 171-8.
19. Tozzi AE, Pandolfi E, Celentano LP, Massari M, Salmaso S, Ciofidegli Atti ML. Comparison of pertussis surveillance systems in Europe. Vaccine. 2007; 25: 291-7.
20. Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: Estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine. 2006; 24: 5960-5.
21. Cortese MM, Baughman AL, Zhang R, Srivastava PU, Wallace GS. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics. 2008; 121: 484-92.
22. Briand V, Bonmarin I, Lévy-Bruhl D. Study of the risk factors for severe childhood pertussis based on hospital surveillance data. Vaccine. 2007; 25: 7224-32.
23. Van Hoek AJ, Campbell H, Amirthalingam G, Andrews N, Miller E. The number of deaths among infants under one year of age in England with pertussis: Results of a capture/recapture analysis forthe period 2001 to 2011. Euro Surveill. 2013; 18: pii=20414.
24. Uriona Tuma SM, Martínez Gómez X, Campins Martí M, Codina Grau G, Ferrer Marcelles A, Rodrigo Pendás JA, et al. Estudio de contactos de casos pediátricos de tos ferina en un hospital de tercer nivel de Barcelona. Med Clin. 2013; 141: 376-81.
25. Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008-2009 pertussis epidemic in NSW: Notifications and hospitalisations. NSW Public Health Bull. 2010; 21: 167-73.
26. O'Brien JA, Caro JJ. Hospitalization for pertussis: Profiles and case costs by age. BMC Infect Dis. 2005; 5: 57.
27. Servei de Vigilància Epidemiològica de la Direcció de Salut Pública. Resultats del programa pilot de vigilància de la tos ferina a Catalunya. Butlletí Epidemiològic de Catalunya. 2005; 26: 1-8.
28. Manzanares S, Lafuente S, Martí M, Simon P, Gorrindo P, Caylà JA. Evolución de la incidencia de tos ferina en laciudad de Barcelona entre 1999 y 2011. Enferm Infecc Microbiol Clin. 2013; 31: 156-8.
29. Gil-Tomás JJ, Colomina-Rodríguez J, Martínez-Macías O, Borrás-Máñez M, González-Morán F, Guerrero-Espejo A. Situación de la tosferina en la Comunidad Valenciana: ¿asistimos a una reactivación epidémica? Enferm Infecc Microbiol Clin. 2013; 31: 590-4.
30. Mertsola J, van der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010; 51: 656-62.
31. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60: 1424-6.
32. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 131-5.
33. Campins M, Moreno-Pérez D, Gil-de Miguel A, González-Romo F, Moraga-Llop FA, Arístegui-Fernández J, et al. Tos ferina en España. Situación epidemiológica y estrategias de prevención y control. Recomendaciones del Grupo de Trabajo de Tos Ferina. Enferm Infecc Microbiol Clin. 2013; 31: 240-53.